Banyu And Santen To Co-promote Glaucoma Combo Drug
This article was originally published in PharmAsia News
Executive Summary
Merck Japanese subsidiary Banyu Pharmaceutical and ophthalmology specialty drug maker Santen Pharmaceutical Feb. 2 signed an agreement to co-promote glaucoma combination drug of Truspot (dorzolamide)/Timoptol (timolol maleate)